OUR TEAM MEMBERS
Caroline Goddeeris holds a PhD in Pharmaceutical Sciences followed by an MBA and master in corporate finance, both from Vlerick Business School. She started her career at UCB taking on various roles in strategy (portfolio management, business development, new product planning) and operations (marketing and sales). Prior to joining Fund+, Caroline was a principal at Gimv with board responsibilities at Complix and Multiplicom (sold to Agilent). Caroline currently serves on the board of Confo Therapeutics, TargED Biopharmaceuticals and Astrivax.
Partner/CFO
Bart joined Fund+ in 2023. Prior to joining Fund+, Bart worked at Ackermans & van Haaren as Group Controller and Investment Manager and as CFO/Risk Officer at Fortino Capital Partners. For most of his career, he worked at Ernst&Young where he progressed as Head of the Technical Desk. He was part of the EY global expert group in London. Bart holds a master’s degree in Commercial Sciences and in Business Information Systems from the University of Brussels.
Principle
Halina Novak holds a Ph.D. in Biological Science from the University of Exeter, UK. She started her career with an industry sponsored postdoctoral fellowship, where she worked on industrial applications of enzymes for Unilever, which resulted in a number of granted patents. Halina went on to work at VIB, at the intersection between industry and academia where she held several positions in Technology and Innovation. Notably, she headed the Tech Watch Program and Technology Innovation Lab, where unique strategies were developed to identify, evaluate and implement breakthrough life science technologies. During her 8 years at VIB, she managed a portfolio of projects with companies developing breakthrough technologies, which resulted in many successful investments in cutting edge tools that have since revolutionised the Life Sciences. Halina currently represents Fund+ as a Board member of Indigo and Cardior, and as a Board Observer of TargED Biopharmaceuticals and EyeD Pharma.